Sign in
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Optic Nerve Head Drusen With Idiopathic CNV
Kristen Wagner
Retina Image Bank: Images of the Week
2017
PRN cycles of three monthly anti-VEGF injections in neovascular AMD: 12 and 24 months results.
Touka Banaee, MD
On Demand Cases, Courses, and Papers
2019
Category: Pediatric Retina